<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kim SY</submitter><funding>NICHD NIH HHS</funding><funding>Foundation for the National Institutes of Health</funding><funding>NIMH NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><pagination>502-515</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6370889</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(3)</volume><pubmed_abstract>Platinum-based chemotherapies can result in ovarian insufficiency by reducing the ovarian reserve, a reduction believed to result from apoptosis of immature oocytes via activation/phosphorylation of TAp63α by multiple kinases including CHEK2, CK1, and ABL1. Here we demonstrate that cisplatin (CDDP) induces oocyte apoptosis through a novel pathway and that temporary repression of this pathway fully preserves ovarian function in vivo. Although ABL kinase inhibitors effectively block CDDP-induced apoptosis of oocytes, oocytic ABL1, and ABL2 are dispensable for damage-induced apoptosis. Instead, CDDP activates TAp63α through the ATR > CHEK1 pathway independent of TAp63α hyper-phosphorylation, whereas X-irradiation activates the ATM > CHEK2 > TAp63α-hyper-phosphorylation pathway. Furthermore, o</pubmed_abstract><journal>Cell death and differentiation</journal><pubmed_title>Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies.</pubmed_title><pmcid>PMC6370889</pmcid><funding_grant_id>P30 CA016058</funding_grant_id><funding_grant_id>P50 HD076188</funding_grant_id><funding_grant_id>50HD076188</funding_grant_id><funding_grant_id>R01 CA154358</funding_grant_id><funding_grant_id>R01 NS039475</funding_grant_id><funding_grant_id>R01 HD064402</funding_grant_id><funding_grant_id>R01 MH115939</funding_grant_id><funding_grant_id>R01 NS089662</funding_grant_id><funding_grant_id>R01 NS105640</funding_grant_id><funding_grant_id>P50HD076188</funding_grant_id><pubmed_authors>Kim SY</pubmed_authors><pubmed_authors>Serna VA</pubmed_authors><pubmed_authors>Nair DM</pubmed_authors><pubmed_authors>Kurita T</pubmed_authors><pubmed_authors>Romero M</pubmed_authors><pubmed_authors>Woodruff TK</pubmed_authors><pubmed_authors>Koleske AJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies.</name><description>Platinum-based chemotherapies can result in ovarian insufficiency by reducing the ovarian reserve, a reduction believed to result from apoptosis of immature oocytes via activation/phosphorylation of TAp63α by multiple kinases including CHEK2, CK1, and ABL1. Here we demonstrate that cisplatin (CDDP) induces oocyte apoptosis through a novel pathway and that temporary repression of this pathway fully preserves ovarian function in vivo. Although ABL kinase inhibitors effectively block CDDP-induced apoptosis of oocytes, oocytic ABL1, and ABL2 are dispensable for damage-induced apoptosis. Instead, CDDP activates TAp63α through the ATR > CHEK1 pathway independent of TAp63α hyper-phosphorylation, whereas X-irradiation activates the ATM > CHEK2 > TAp63α-hyper-phosphorylation pathway. Furthermore, o</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Mar</publication><modification>2026-07-14T14:55:15.89Z</modification><creation>2025-04-05T20:37:36.513Z</creation></dates><accession>S-EPMC6370889</accession><cross_references><pubmed>29988075</pubmed><doi>10.1038/s41418-018-0151-2</doi></cross_references></HashMap>